| Autor: |
Rizk, John G., Lazo Jr., Jose G., Gupta, Aashish, Lavie, Carl J., Effron, Mark B. |
| Předmět: |
|
| Zdroj: |
Seminars in Thrombosis & Hemostasis; Feb2023, Vol. 49 Issue 1, p85-88, 4p |
| Abstrakt: |
In December 2021, the U.S. Food and Drug Administration (FDA) issued emergency use authorizations (EUAs) for two oral antiviral at-home treatments for coronavirus disease 2019 (COVID-19), nirmatrelvir/ritonavir (Paxlovid [Pfizer]), and molnupiravir (Merck). 1995, 333, 23, 1528-1533 10 The COVID-19 treatment guidelines panel's statement on the role of bebtelovimab for the treatment of high-risk, nonhospitalized patients with mild to moderate COVID-19. Proposal for a Simple Algorithmic Approach to Manage Drug-Drug Interactions of Oral Anticoagulants with Nirmatrelvir/Ritonavir in COVID-19 Outpatients. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
